ArticleMaterials today. Bio2026
Ferrostatin-1-loaded black phosphorus quantum dots (BPQD@Fer-1) nanodelivery system attenuates T cell-mediated rejection after kidney transplantation.
Article in Materials today. Bio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The long-term viability of kidney transplantation is commonly hindered by initial ischemia-reperfusion injury (IRI) and the ensuing T cell-mediated rejection (TCMR). Upon reperfusion, the inevitable IRI provokes an acute surge of reactive oxygen species (ROS), thereby driving profound tubular ferroptosis. Dying cells release damage-associated molecular patterns (DAMPs) that attract alloreactive T cells, intensifying oxidative stress and ferroptosis in a destructive feedback loop. To alleviate the severity of TCMR, we developed ultra-small black phosphorus quantum dots (BPQD) loaded with ferrostatin-1, a ferroptosis inhibitor (BPQD@Fer-1 nanoparticles) delivered directly via
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.